RPG Life Sciences share news, announcements and annual reports
NSE: RPGLIFEBSE: 532983Pharmaceuticals & BiotechnologySmall Cap
RPG Life Sciences Limited · Face value ₹8 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008
Last close ₹3,003.80up ₹159.80 (5.62%)BSE ₹2,995.65
Share price at the NSE close on 29 Oct 2026. Previous close ₹2,844.00.
29 Oct: open ₹2,780.00, high ₹3,050.00, low ₹2,779.90
52-week range of traded prices to 29 Oct 2026
₹1,733.00Low, 23 Mar 2026₹3,127.80High, 25 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,968 Cr923rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 45.42
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 7.23
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.80%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it, the company's own balance sheet from before it began consolidating; the two agree where both are first on record.
- 17.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,36,34643.2% delivered
RPG Life Sciences board meetings
120 filed, newest first. Page 3 of 3.
Oct 2012
12 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended September 30, 2012.
Jul 2012
30 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended June 30, 2012.
Apr 2012
27 Apr · Board meeting
At the Board Meeting held on April 27, 2012 : (1) Mr. Dilip Sen resigned from the Directorship of the Company w.e.f. April 18, 2012; (2) Mr. C. Vinayaraghavan was appointed as Director of the Company w.e.f. April 27, 2012, in the casual vacancy caused due to the resignation of Mr. Dilip Sen; (3) Mr. R.A. Shah was appointed as Alternate Director to Mr. C. Vinayaraghavan w.e.f. April 27, 2012.13 Apr · Board meeting
Interalia, to consider and approve the following : (1) Audited Financial Results for the year ended on March 31, 2012; and (2) Recommendation of dividend for the year 2011-12, if any.
Jan 2012
12 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended December 31, 2011.
Oct 2011
7 Oct · Board meeting
Inter-alia, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2011.
Jul 2011
8 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended June 30, 2011.
Apr 2011
15 Apr · Board meeting
Inter alia, to consider and approve the following : (1) Audited Financial Results for the year ended on March 31, 2011; and (2) Recommendation of dividend for the year 2010-11, if any.
Jan 2011
6 Jan · Board meeting
Inter-alia, to consider and approve the unaudited financial results for the quarter ended on December 31, 2010.
Oct 2010
11 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2010.
Jul 2010
19 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended June 30, 2010.
May 2010
4 May · Board meeting
Inter alia, to consider and approve the following: (1) Audited Financial Results for the year ended on March 31, 2010; and (2) Recommendation of dividend for the year 2009-10, if any.
Jan 2010
7 Jan · Board meeting
Meeting on 19 Jan 2010: “Unaudited Financial Results for the qtr ended Dec 31, 2009”
Oct 2009
20 Oct · Board meeting
Meeting on 28 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
20 Jul · Board meeting
Meeting on 29 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
Jun 2009
17 Jun · Board meeting
Inter alia, to consider and approve the following: (1) Audited financial results for the year ended on March 31, 2009; and (2) Recommendation of dividend for the year 2008-09, if any.
Jan 2009
21 Jan · Board meeting
Meeting on 29 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
15 Oct · Board meeting
Meeting on 23 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”
Jul 2008
18 Jul · Board meeting
Meeting on 31 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Jun 2008
17 Jun · Board meeting
Inter-alia, to consider and approve the audited financial results for the period ended on March 31, 2008.